KBC Group’s Relay Therapeutics RLAY Stock Holding History

KBC Group’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$65K	Hold	3,448	–	–	﹤0.01%	1625
2026 Q1	$34K	Buy	+3,448	New	+$30.8K	﹤0.01%	1771

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

KBC Group's RLAY Position: Q2 2026 in Review

KBC Group held its Relay Therapeutics (RLAY) position steady in Q2 2026 at 3,448 shares worth $65K. The position accounts for ﹤0.01% of the portfolio, ranked #1625.

KBC Group first reported a position in RLAY in Q1 2026 and has held it in 2 quarters since. 260 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

KBC Group held 3,448 shares of Relay Therapeutics worth $65K as of Q2 2026.
KBC Group left its Relay Therapeutics share count unchanged in Q2 2026.
Relay Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1625 holding.
KBC Group first reported a position in Relay Therapeutics in Q1 2026 and has held it in 2 quarters since.
260 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.